Share Price and Basic Stock Data
Last Updated: November 19, 2025, 11:59 pm
| PEG Ratio | -5.36 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Dhampur Bio Organics Ltd operates within the sugar industry, with its stock currently priced at ₹71.0 and a market capitalization of ₹471 Cr. The company reported a total sales figure of ₹2,408 Cr for the financial year ending March 2023, a significant increase from ₹1,564 Cr in March 2022. However, this was followed by a decline to ₹1,864 Cr in March 2024 and a marginal decrease to ₹1,862 Cr in March 2025. The trailing twelve months (TTM) revenue stood at ₹2,012 Cr, indicating fluctuations in sales performance. Quarterly sales figures showed a peak of ₹803 Cr in March 2023, but subsequently fell to ₹280 Cr in December 2023, reflecting volatility in revenue generation. The company’s operational efficiency is indicated by its cash conversion cycle (CCC), which was reported at 270 days as of March 2025, underscoring challenges in inventory management and receivables collection compared to typical industry standards.
Profitability and Efficiency Metrics
Profitability metrics for Dhampur Bio Organics Ltd reveal a complex picture. The operating profit margin (OPM) was recorded at 0% for the most recent quarter, reflecting significant operational challenges. Over the past year, the OPM fluctuated with a peak of 14% in March 2023, followed by a decline to 7% in June 2023, and dropping to negative margins in subsequent quarters. The net profit recorded a loss of ₹6 Cr in December 2023, highlighting the company’s struggle to maintain profitability. The interest coverage ratio (ICR) stood at 2.06x in March 2025, indicating that the company earns just over twice its interest obligations, which is a concern given its rising interest expenses, escalating from ₹30 lakh in March 2022 to ₹67 lakh by March 2025. The return on equity (ROE) was a modest 1.56%, suggesting limited returns for shareholders amidst this profitability decline.
Balance Sheet Strength and Financial Ratios
The balance sheet of Dhampur Bio Organics Ltd presents several areas of concern. The company’s total debt to equity ratio stood at 1.14x as of March 2025, which indicates a higher reliance on debt financing compared to equity, raising caution regarding financial leverage. Despite this, the company reported no reserves or borrowings, suggesting a lack of retained earnings to support growth initiatives. The book value per share was ₹152.39, while the price-to-book value ratio was a low 0.43x, indicating that the stock is trading at a significant discount to its book value, potentially attracting value investors. However, the company’s current ratio of 1.14x reflects a slightly above-average liquidity position, which may not be sufficient to cover short-term obligations in the face of declining sales and profitability metrics. The inventory turnover ratio at 1.25x suggests inefficiencies in inventory management, posing additional risks to operational performance.
Shareholding Pattern and Investor Confidence
Investor confidence in Dhampur Bio Organics Ltd appears mixed, as evidenced by its shareholding pattern. Promoters hold a substantial 50.65% stake, indicating strong insider confidence in the company’s long-term prospects. However, foreign institutional investors (FIIs) have reduced their holdings significantly from 6.63% in December 2022 to just 0.35% by March 2025, reflecting a lack of confidence among international investors. Domestic institutional investors (DIIs) have also maintained a minimal presence with a holding of only 0.45%. Public shareholding stood at 47.67%, suggesting that retail investors are the primary shareholders. The number of shareholders declined from 55,770 in December 2022 to 48,055 in September 2025, indicating potential disenchantment among smaller investors. This shift in shareholding dynamics raises questions about the company’s ability to attract new investors and retain existing ones amidst its financial challenges.
Outlook, Risks, and Final Insight
Looking ahead, Dhampur Bio Organics Ltd faces significant risks that could impact its operational viability. The volatility in sales and profitability metrics underscores the challenges in maintaining a stable revenue stream. Furthermore, the dependence on debt financing alongside rising interest expenses could strain cash flows, particularly if sales do not rebound. On the other hand, the company’s low price-to-book value ratio may present a buying opportunity for value-oriented investors if the management can implement strategies to enhance profitability. Additionally, potential recovery in sugar prices and improved operational efficiencies could provide a pathway for growth. However, the company’s ability to navigate these risks effectively will be crucial for restoring investor confidence and achieving sustainable financial performance in the coming quarters.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Dhampur Bio Organics Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gayatri Sugars Ltd | 93.5 Cr. | 12.6 | 18.8/7.02 | 334 | 16.8 | 0.00 % | 36.6 % | % | 10.0 |
| Dhampure Speciality Sugars Ltd | 87.6 Cr. | 100 | 142/82.0 | 22.2 | 45.3 | 0.00 % | 11.6 % | 8.88 % | 10.0 |
| Dhampur Bio Organics Ltd | 471 Cr. | 71.0 | 134/57.3 | 275 | 145 | 1.76 % | 3.97 % | 1.56 % | 10.0 |
| DCM Shriram Industries Ltd | 1,443 Cr. | 166 | 214/142 | 23.7 | 105 | 1.20 % | 13.7 % | 11.8 % | 2.00 |
| Davangere Sugar Company Ltd | 526 Cr. | 3.68 | 12.4/3.03 | 41.6 | 3.52 | 0.00 % | 6.70 % | 3.17 % | 1.00 |
| Industry Average | 1,830.56 Cr | 268.59 | 45.88 | 225.56 | 0.68% | 8.62% | 7.89% | 6.37 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 496 | 515 | 594 | 803 | 583 | 538 | 280 | 463 | 467 | 466 | 464 | 464 | 526 |
| Expenses | 464 | 493 | 559 | 687 | 543 | 519 | 284 | 382 | 434 | 476 | 448 | 369 | 524 |
| Operating Profit | 32 | 22 | 34 | 116 | 41 | 19 | -4 | 81 | 33 | -10 | 16 | 96 | 1 |
| OPM % | 6% | 4% | 6% | 14% | 7% | 4% | -2% | 18% | 7% | -2% | 3% | 21% | 0% |
| Other Income | 3 | 6 | 1 | 2 | 2 | 1 | 16 | 5 | 1 | 1 | -1 | 1 | 2 |
| Interest | 14 | 9 | 5 | 13 | 13 | 9 | 6 | 18 | 21 | 16 | 10 | 20 | 22 |
| Depreciation | 8 | 9 | 10 | 13 | 11 | 10 | 14 | 14 | 12 | 11 | 15 | 16 | 14 |
| Profit before tax | 12 | 11 | 20 | 92 | 18 | 0 | -8 | 54 | 1 | -35 | -10 | 61 | -33 |
| Tax % | 29% | 28% | 26% | 13% | 32% | 88% | -28% | 28% | 83% | -34% | -32% | 26% | -33% |
| Net Profit | 8 | 8 | 15 | 80 | 13 | 0 | -6 | 39 | 0 | -23 | -7 | 45 | -22 |
| EPS in Rs | 1.24 | 1.16 | 2.26 | 12.08 | 1.91 | 0.01 | -0.85 | 5.94 | 0.02 | -3.52 | -1.03 | 6.75 | -3.31 |
Last Updated: August 19, 2025, 8:10 pm
Below is a detailed analysis of the quarterly data for Dhampur Bio Organics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 526.00 Cr.. The value appears strong and on an upward trend. It has increased from 464.00 Cr. (Mar 2025) to 526.00 Cr., marking an increase of 62.00 Cr..
- For Expenses, as of Jun 2025, the value is 524.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 369.00 Cr. (Mar 2025) to 524.00 Cr., marking an increase of 155.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 96.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 95.00 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value appears to be declining and may need further review. It has decreased from 21.00% (Mar 2025) to 0.00%, marking a decrease of 21.00%.
- For Other Income, as of Jun 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 22.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 20.00 Cr. (Mar 2025) to 22.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Jun 2025, the value is 14.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 2.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -33.00 Cr.. The value appears to be declining and may need further review. It has decreased from 61.00 Cr. (Mar 2025) to -33.00 Cr., marking a decrease of 94.00 Cr..
- For Tax %, as of Jun 2025, the value is -33.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Mar 2025) to -33.00%, marking a decrease of 59.00%.
- For Net Profit, as of Jun 2025, the value is -22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 45.00 Cr. (Mar 2025) to -22.00 Cr., marking a decrease of 67.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -3.31. The value appears to be declining and may need further review. It has decreased from 6.75 (Mar 2025) to -3.31, marking a decrease of 10.06.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:31 am
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Sales | 0 | 1,564 | 2,408 | 1,864 | 1,862 | 2,012 |
| Expenses | 0 | 1,381 | 2,203 | 1,724 | 1,727 | 1,907 |
| Operating Profit | -0 | 183 | 205 | 140 | 135 | 105 |
| OPM % | 12% | 8% | 8% | 7% | 5% | |
| Other Income | 0 | 8 | 11 | 20 | 2 | 15 |
| Interest | 0 | 30 | 41 | 45 | 67 | 66 |
| Depreciation | 0 | 31 | 41 | 49 | 54 | 60 |
| Profit before tax | -0 | 129 | 135 | 65 | 16 | -6 |
| Tax % | 0% | 21% | 18% | 29% | 6% | |
| Net Profit | -0 | 102 | 111 | 46 | 15 | -0 |
| EPS in Rs | 16.74 | 7.00 | 2.21 | -0.00 | ||
| Dividend Payout % | 0% | 0% | 21% | 36% | 56% |
YoY Net Profit Growth
| Year | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | 8.82% | -58.56% | -67.39% |
| Change in YoY Net Profit Growth (%) | 0.00% | -67.38% | -8.83% |
Dhampur Bio Organics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 6% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -46% |
| TTM: | -117% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -38% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 6% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 3:11 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debtor Days | 25 | 23 | 17 | 11 | |
| Inventory Days | 341 | 163 | 288 | 288 | |
| Days Payable | 54 | 33 | 37 | 29 | |
| Cash Conversion Cycle | 312 | 154 | 269 | 270 | |
| Working Capital Days | 56 | 24 | 33 | 21 | |
| ROCE % | 11% | 10% | 5% | 4% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 2.21 | 7.00 | 16.74 | 15.35 | 0.00 |
| Diluted EPS (Rs.) | 2.21 | 7.00 | 16.74 | 15.35 | 0.00 |
| Cash EPS (Rs.) | 10.33 | 14.46 | 22.84 | 20.06 | 0.00 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 152.39 | 152.35 | 148.93 | 132.16 | 116.73 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 152.39 | 152.35 | 148.93 | 132.16 | 116.73 |
| Revenue From Operations / Share (Rs.) | 280.39 | 280.83 | 362.63 | 232.10 | 0.00 |
| PBDIT / Share (Rs.) | 20.86 | 24.15 | 32.56 | 28.68 | 0.00 |
| PBIT / Share (Rs.) | 12.74 | 16.69 | 26.45 | 23.96 | 0.00 |
| PBT / Share (Rs.) | 2.37 | 9.86 | 20.30 | 19.43 | 0.00 |
| Net Profit / Share (Rs.) | 2.21 | 7.00 | 16.73 | 15.35 | 0.00 |
| NP After MI And SOA / Share (Rs.) | 2.21 | 7.00 | 16.73 | 15.35 | 0.00 |
| PBDIT Margin (%) | 7.43 | 8.59 | 8.97 | 12.35 | 0.00 |
| PBIT Margin (%) | 4.54 | 5.94 | 7.29 | 10.32 | 0.00 |
| PBT Margin (%) | 0.84 | 3.51 | 5.59 | 8.36 | 0.00 |
| Net Profit Margin (%) | 0.78 | 2.49 | 4.61 | 6.61 | 0.00 |
| NP After MI And SOA Margin (%) | 0.78 | 2.49 | 4.61 | 6.61 | 0.00 |
| Return on Networth / Equity (%) | 1.45 | 4.59 | 11.23 | 11.61 | 0.00 |
| Return on Capital Employeed (%) | 6.42 | 8.78 | 14.41 | 15.23 | 0.00 |
| Return On Assets (%) | 0.61 | 2.01 | 5.34 | 5.09 | 0.00 |
| Long Term Debt / Equity (X) | 0.23 | 0.17 | 0.17 | 0.11 | 0.12 |
| Total Debt / Equity (X) | 1.14 | 1.03 | 0.81 | 0.93 | 0.50 |
| Asset Turnover Ratio (%) | 0.79 | 0.84 | 1.18 | 0.86 | 0.00 |
| Current Ratio (X) | 1.14 | 1.19 | 1.31 | 1.28 | 1.46 |
| Quick Ratio (X) | 0.12 | 0.16 | 0.35 | 0.17 | 0.29 |
| Inventory Turnover Ratio (X) | 1.25 | 1.69 | 1.69 | 1.62 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 113.00 | 49.96 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 24.20 | 24.20 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | -13.00 | 50.04 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 75.80 | 75.80 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 2.06 | 3.54 | 5.29 | 6.32 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | 1.25 | 2.03 | 3.72 | 4.38 | 0.00 |
| Enterprise Value (Cr.) | 1553.77 | 1776.49 | 1647.22 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 0.83 | 0.95 | 0.68 | 0.00 | 0.00 |
| EV / EBITDA (X) | 11.22 | 11.08 | 7.62 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.23 | 0.40 | 0.39 | 0.00 | 0.00 |
| Retention Ratios (%) | -13.00 | 50.03 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 0.43 | 0.75 | 0.96 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 0.23 | 0.40 | 0.39 | 0.00 | 0.00 |
| EarningsYield | 0.03 | 0.06 | 0.11 | 0.00 | 0.00 |
After reviewing the key financial ratios for Dhampur Bio Organics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.21. This value is below the healthy minimum of 5. It has decreased from 7.00 (Mar 24) to 2.21, marking a decrease of 4.79.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.21. This value is below the healthy minimum of 5. It has decreased from 7.00 (Mar 24) to 2.21, marking a decrease of 4.79.
- For Cash EPS (Rs.), as of Mar 25, the value is 10.33. This value is within the healthy range. It has decreased from 14.46 (Mar 24) to 10.33, marking a decrease of 4.13.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 152.39. It has increased from 152.35 (Mar 24) to 152.39, marking an increase of 0.04.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 152.39. It has increased from 152.35 (Mar 24) to 152.39, marking an increase of 0.04.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 280.39. It has decreased from 280.83 (Mar 24) to 280.39, marking a decrease of 0.44.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 20.86. This value is within the healthy range. It has decreased from 24.15 (Mar 24) to 20.86, marking a decrease of 3.29.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.74. This value is within the healthy range. It has decreased from 16.69 (Mar 24) to 12.74, marking a decrease of 3.95.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.37. This value is within the healthy range. It has decreased from 9.86 (Mar 24) to 2.37, marking a decrease of 7.49.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.21. This value is within the healthy range. It has decreased from 7.00 (Mar 24) to 2.21, marking a decrease of 4.79.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 2.21. This value is within the healthy range. It has decreased from 7.00 (Mar 24) to 2.21, marking a decrease of 4.79.
- For PBDIT Margin (%), as of Mar 25, the value is 7.43. This value is below the healthy minimum of 10. It has decreased from 8.59 (Mar 24) to 7.43, marking a decrease of 1.16.
- For PBIT Margin (%), as of Mar 25, the value is 4.54. This value is below the healthy minimum of 10. It has decreased from 5.94 (Mar 24) to 4.54, marking a decrease of 1.40.
- For PBT Margin (%), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 10. It has decreased from 3.51 (Mar 24) to 0.84, marking a decrease of 2.67.
- For Net Profit Margin (%), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 5. It has decreased from 2.49 (Mar 24) to 0.78, marking a decrease of 1.71.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 8. It has decreased from 2.49 (Mar 24) to 0.78, marking a decrease of 1.71.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 15. It has decreased from 4.59 (Mar 24) to 1.45, marking a decrease of 3.14.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.42. This value is below the healthy minimum of 10. It has decreased from 8.78 (Mar 24) to 6.42, marking a decrease of 2.36.
- For Return On Assets (%), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 5. It has decreased from 2.01 (Mar 24) to 0.61, marking a decrease of 1.40.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has increased from 0.17 (Mar 24) to 0.23, marking an increase of 0.06.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.14. This value exceeds the healthy maximum of 1. It has increased from 1.03 (Mar 24) to 1.14, marking an increase of 0.11.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.79. It has decreased from 0.84 (Mar 24) to 0.79, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 1.5. It has decreased from 1.19 (Mar 24) to 1.14, marking a decrease of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 0.12. This value is below the healthy minimum of 1. It has decreased from 0.16 (Mar 24) to 0.12, marking a decrease of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.25. This value is below the healthy minimum of 4. It has decreased from 1.69 (Mar 24) to 1.25, marking a decrease of 0.44.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 113.00. This value exceeds the healthy maximum of 50. It has increased from 49.96 (Mar 24) to 113.00, marking an increase of 63.04.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 24.20. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 24.20.
- For Earning Retention Ratio (%), as of Mar 25, the value is -13.00. This value is below the healthy minimum of 40. It has decreased from 50.04 (Mar 24) to -13.00, marking a decrease of 63.04.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 75.80. This value exceeds the healthy maximum of 70. There is no change compared to the previous period (Mar 24) which recorded 75.80.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.06. This value is below the healthy minimum of 3. It has decreased from 3.54 (Mar 24) to 2.06, marking a decrease of 1.48.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.25. This value is below the healthy minimum of 3. It has decreased from 2.03 (Mar 24) to 1.25, marking a decrease of 0.78.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,553.77. It has decreased from 1,776.49 (Mar 24) to 1,553.77, marking a decrease of 222.72.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 0.95 (Mar 24) to 0.83, marking a decrease of 0.12.
- For EV / EBITDA (X), as of Mar 25, the value is 11.22. This value is within the healthy range. It has increased from 11.08 (Mar 24) to 11.22, marking an increase of 0.14.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 1. It has decreased from 0.40 (Mar 24) to 0.23, marking a decrease of 0.17.
- For Retention Ratios (%), as of Mar 25, the value is -13.00. This value is below the healthy minimum of 30. It has decreased from 50.03 (Mar 24) to -13.00, marking a decrease of 63.03.
- For Price / BV (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.43, marking a decrease of 0.32.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 1. It has decreased from 0.40 (Mar 24) to 0.23, marking a decrease of 0.17.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to 0.03, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dhampur Bio Organics Ltd:
- Net Profit Margin: 0.78%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.42% (Industry Average ROCE: 8.62%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.45% (Industry Average ROE: 7.89%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.25
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.12
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 275 (Industry average Stock P/E: 45.88)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.14
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.78%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Sugar | Sugar Mill Compound, Village & Post - Asmoli, Sambhal Dist. Uttar Pradesh 244304 | investors@dhampur.com http://www.dhampur.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Vijay Kumar Goel | Chairman |
| Mr. Ashwani Kumar Gupta | Vice Chairman |
| Mr. Gautam Goel | Managing Director & CEO |
| Mr. Sandeep Kumar | Whole Time Director |
| Mrs. Bindu Vashist Goel | Non Executive Director |
| Mrs. Ruchika Amrish Mehra Kothari | Independent Director |
| Mr. Vishal Saluja | Independent Director |
| Mr. Samir Thukral | Independent Director |
| Mr. Kishor Shah | Independent Director |